- Home
- QNCX vs MGNX Comparison
QNCX vs MGNX Comparison
Compare QNCX & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNCX
- MGNX
- Stock Information
- Founded
- QNCX 2012
- MGNX 2000
- Country
- QNCX United States
- MGNX United States
- Employees
- QNCX N/A
- MGNX N/A
- Industry
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- QNCX Health Care
- MGNX Health Care
- Exchange
- QNCX Nasdaq
- MGNX Nasdaq
- Market Cap
- QNCX 90.8M
- MGNX 99.7M
- IPO Year
- QNCX 2019
- MGNX 2013
- Fundamental
- Price
- QNCX $1.60
- MGNX $1.59
- Analyst Decision
- QNCX Strong Buy
- MGNX Hold
- Analyst Count
- QNCX 6
- MGNX 5
- Target Price
- QNCX $8.00
- MGNX $3.25
- AVG Volume (30 Days)
- QNCX 124.9K
- MGNX 960.4K
- Earning Date
- QNCX 11-12-2025
- MGNX 11-04-2025
- Dividend Yield
- QNCX N/A
- MGNX N/A
- EPS Growth
- QNCX N/A
- MGNX N/A
- EPS
- QNCX N/A
- MGNX N/A
- Revenue
- QNCX N/A
- MGNX $165,495,000.00
- Revenue This Year
- QNCX N/A
- MGNX N/A
- Revenue Next Year
- QNCX N/A
- MGNX N/A
- P/E Ratio
- QNCX N/A
- MGNX N/A
- Revenue Growth
- QNCX N/A
- MGNX 303.47
- 52 Week Low
- QNCX $0.69
- MGNX $0.99
- 52 Week High
- QNCX $2.45
- MGNX $5.10
- Technical
- Relative Strength Index (RSI)
- QNCX 47.89
- MGNX 45.01
- Support Level
- QNCX $1.56
- MGNX $1.68
- Resistance Level
- QNCX $1.65
- MGNX $1.77
- Average True Range (ATR)
- QNCX 0.08
- MGNX 0.16
- MACD
- QNCX 0.00
- MGNX -0.02
- Stochastic Oscillator
- QNCX 64.65
- MGNX 3.08
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.